Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

611 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
LePrevost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM; Pediatric European Network for the Treatment of AIDS 13 Study Group. LePrevost M, et al. Among authors: walker as. Pediatr Infect Dis J. 2006 Jun;25(6):533-7. doi: 10.1097/01.inf.0000222415.40563.d4. Pediatr Infect Dis J. 2006. PMID: 16732152
Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.
Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A. Pillay D, et al. Among authors: walker as. J Infect Dis. 2002 Sep 1;186(5):617-25. doi: 10.1086/342680. Epub 2002 Aug 9. J Infect Dis. 2002. PMID: 12195348 Clinical Trial.
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM, Walker AS, Kaye S, De Rossi A, Ait-Khaled M, Pillay D, Muñoz-Fernandez MA, Loveday C, Compagnucci A, Dunn DT, Babiker AG. Gibb DM, et al. Among authors: walker as. Antivir Ther. 2002 Dec;7(4):293-303. Antivir Ther. 2002. PMID: 12553485 Clinical Trial.
Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
Gibb DM, Duong T, Leclezio VA, Walker AS, Verweel G, Dunn DT; Collaborative HIV Paediatric Study Steering Committee. Gibb DM, et al. Among authors: walker as. Pediatr Infect Dis J. 2004 May;23(5):446-50. doi: 10.1097/01.inf.0000122601.62358.74. Pediatr Infect Dis J. 2004. PMID: 15131469 Clinical Trial.
Clinical trials in children.
Menson EN, Walker AS, Gibb DM. Menson EN, et al. Among authors: walker as. Lancet. 2004 Dec 18-31;364(9452):2176-7. doi: 10.1016/S0140-6736(04)17581-8. Lancet. 2004. PMID: 15610796 No abstract available.
Outcomes for human immunodeficiency virus-1-infected infants in the United kingdom and Republic of Ireland in the era of effective antiretroviral therapy.
Doerholt K, Duong T, Tookey P, Butler K, Lyall H, Sharland M, Novelli V, Riordan A, Dunn D, Walker AS, Gibb DM; Collaborative HIV Paediatric Study. Doerholt K, et al. Among authors: walker as. Pediatr Infect Dis J. 2006 May;25(5):420-6. doi: 10.1097/01.inf.0000214994.44346.d3. Pediatr Infect Dis J. 2006. PMID: 16645506
611 results